https://www.selleckchem.com/pr....oducts/ly2780301.htm
The HER2 + tumor immune microenvironment is composed of macrophages, natural killer cells, and tumor infiltrating lymphocytes, which produce pro-inflammatory cytokines. Determining the effect of T-cells on HER2 + cancer cells during therapy could guide immunogenic therapies that trigger antibody-dependent cellular cytotoxicity. This study utilized longitudinal in vitro time-resolved microscopy to measure T-cell influence on trastuzumab in HER2 + breast cancer. Fluorescently-labeled breast cancer cells (BT474, SKBR3, MDA-MB-453, and MD
Like
Comment
Share
